Tocilizumab
- Generic Name
- Tocilizumab
- Brand Names
- Actemra, RoActemra, Tyenne, Tofidence
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 375823-41-9
- Unique Ingredient Identifier
- I031V2H011
- Background
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...
- Indication
Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- Monotherapy
TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- FMH College of Medicine and Dentistry
- Target Recruit Count
- 93
- Registration Number
- NCT04730323
- Locations
- 🇵🇰
Fatima Memorial Hospital College of Medicine & Dentistry, Lahore, Punjab, Pakistan
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT04729959
- Locations
- 🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States
🇺🇸Kaiser Permanente-Bellflower, Bellflower, California, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
- Conditions
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- M Abdur Rahim Medical College and Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT04693026
- Locations
- 🇧🇩
M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh
Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- University of Lahore
- Target Recruit Count
- 200
- Registration Number
- NCT04690920
- Locations
- 🇵🇰
The University of Lahore, Lahore, Punjab, Pakistan
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 28
- Registration Number
- NCT04691817
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 25
- Registration Number
- NCT04687540
- Locations
- 🇩🇰
Rigshospitalet, Centre of Inflammation and Metabolism (CIM) Centre for Physical Activity Research (CFAS), Copenhagen, Denmark
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Yi Luo
- Target Recruit Count
- 46
- Registration Number
- NCT04688021
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- M Abdur Rahim Medical College and Hospital
- Target Recruit Count
- 205
- Registration Number
- NCT04678739
- Locations
- 🇧🇩
Chattogram General Hospital, Chittagong, Bangladesh
🇧🇩Cox's Bazar 250 Bed District Sadar Hospital, Cox's Bazar, Bangladesh
🇧🇩M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT04657302
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, China
🇨🇳Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology, Guangzhou City, China
🇨🇳Beijing Cancer Hospital, Beijing, China
Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 20
- Registration Number
- NCT04652258
- Locations
- 🇨🇭
University Hospital Zurich, Clinic of Dermatology, Zürich, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.